Novavax, Inc. (NVAX) — closed signal from October 31, 2025
Partial Published before the outcome was known, scored automatically when the window closed on January 29, 2026.
Predicted vs. what happened
What happened
Reached 47% of the predicted growth at its peak, without hitting the target.
The thesis — published October 31, 2025
Novavax is reshaping its business to earn fees by licensing its vaccines. Recent news confirmed a $25M payment from Sanofi and a site sale to AstraZeneca, giving it more cash to fund the shift. The stock is still shaky, so start small near the current range and add only if the trend clearly turns up. Over the next 0-3 months, more partner payments could lift shares, but results and steady funding remain the main risks.
Primary drivers
- Sanofi's $25M payment supports the move to a licensing-focused model
- Selling a facility brings in cash, helping fund operations and reduce risk
- Upcoming partner news could change how investors value the company
- Shaky price action means waiting for clear signs of renewed buyer interest
How it played out
NVAX: thesis rose but never reached the target
Lyra published NVAX at $8.41 on 2025-10-31 with expected growth of 45%. The thesis pointed to a shift toward vaccine licensing fees, Sanofi's $25M payment, a facility sale that added cash, possible partner news, and the risk that price action was still shaky.
Inside the window, the stock rose, but it did not reach the $12.19 target. Its peak was $10.20 on 2026-01-27, a 21.3% gain. It ended at $9.44 on 2026-01-29. The thesis partly played out on direction, but it missed the full target. It never got there.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.